These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 23192654)
1. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients. Salvatorelli E; Menna P; Paz OG; Chello M; Covino E; Singer JW; Minotti G J Pharmacol Exp Ther; 2013 Feb; 344(2):467-78. PubMed ID: 23192654 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin. Salvatorelli E; Menna P; Gonzalez Paz O; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G J Pharmacol Exp Ther; 2012 May; 341(2):474-83. PubMed ID: 22338034 [TBL] [Abstract][Full Text] [Related]
3. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Cavalletti E; Crippa L; Mainardi P; Oggioni N; Cavagnoli R; Bellini O; Sala F Invest New Drugs; 2007 Jun; 25(3):187-95. PubMed ID: 17285358 [TBL] [Abstract][Full Text] [Related]
4. Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies. Salvatorelli E; Menna P; Gianni L; Minotti G J Pharmacol Exp Ther; 2007 Feb; 320(2):790-800. PubMed ID: 17135345 [TBL] [Abstract][Full Text] [Related]
5. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. Salvatorelli E; Menna P; Cascegna S; Liberi G; Calafiore AM; Gianni L; Minotti G J Pharmacol Exp Ther; 2006 Jul; 318(1):424-33. PubMed ID: 16614166 [TBL] [Abstract][Full Text] [Related]
6. Pixantrone: novel mode of action and clinical readouts. Minotti G; Han H; Cattan V; Egorov A; Bertoni F Expert Rev Hematol; 2018 Jul; 11(7):587-596. PubMed ID: 29912583 [TBL] [Abstract][Full Text] [Related]
7. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity. Minotti G; Cavaliere AF; Mordente A; Rossi M; Schiavello R; Zamparelli R; Possati G J Clin Invest; 1995 Apr; 95(4):1595-605. PubMed ID: 7706466 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma. Jamal-Hanjani M; Pettengell R Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1441-8. PubMed ID: 21905966 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin. Salvatorelli E; Menna P; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G J Pharmacol Exp Ther; 2012 May; 341(2):464-73. PubMed ID: 22338033 [TBL] [Abstract][Full Text] [Related]
10. Rethinking Drugs from Chemistry to Therapeutic Opportunities: Pixantrone beyond Anthracyclines. Menna P; Salvatorelli E; Minotti G Chem Res Toxicol; 2016 Aug; 29(8):1270-8. PubMed ID: 27420111 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform. Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439 [TBL] [Abstract][Full Text] [Related]
12. Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity. Minotti G; Mancuso C; Frustaci A; Mordente A; Santini SA; Calafiore AM; Liberi G; Gentiloni N J Clin Invest; 1996 Aug; 98(3):650-61. PubMed ID: 8698856 [TBL] [Abstract][Full Text] [Related]
13. Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues. Stewart DJ; Grewaal D; Green RM; Mikhael N; Goel R; Montpetit VA; Redmond MD Anticancer Res; 1993; 13(6A):1945-52. PubMed ID: 8297100 [TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles? Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427 [TBL] [Abstract][Full Text] [Related]
15. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Doroshow JH Cancer Res; 1983 Feb; 43(2):460-72. PubMed ID: 6293697 [TBL] [Abstract][Full Text] [Related]
17. Pixantrone for the treatment of aggressive non-Hodgkin lymphoma. Mukherji D; Pettengell R Expert Opin Pharmacother; 2010 Aug; 11(11):1915-23. PubMed ID: 20569087 [TBL] [Abstract][Full Text] [Related]
18. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort. Srokowski TP; Liebmann JE; Modiano MR; Cohen GI; Pro B; Romaguera JE; Kuepfer C; Singer JW; Fayad LE Cancer; 2011 Nov; 117(22):5067-73. PubMed ID: 21681734 [TBL] [Abstract][Full Text] [Related]